India will tighten scrutiny over foreign takeovers of Indian pharmaceutical firms as part of discussions meant to ease concerns over the domestic drug industry in the country.

From now, "brownfield" investments, proposals for mergers and acquisitions of Indian pharmaceutical firms will be examined by the Foreign Investment Promotion board for up to six months.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Competition Commission of India, which will receive strengthened powers as part of the reforms, will scrutinise proposed deals to determine any implications on the domestic drug market.

The move comes after health officials expressed concerns that India’s foreign direct investment regime has been culpable of making some medicines less affordable by the Indian population.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now